Cipla receives 7 observations for its API manufacturing facility in Virgonangar, Bengaluru

Image
Capital Market
Last Updated : Jul 20 2019 | 4:50 PM IST
Cipla announced that the USFDA conducted a routine cGMP inspection at its API manufacturing facility in Virgonangar, Bengaluru, from 15 July 2019 to 19 July 2019.

The inspection ended with 7 observations, none of which were repeat or related to data integrity. The Company will respond to the agency within the stipulated timeline.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Jul 20 2019 | 4:20 PM IST

Next Story